Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J-Merck Pepcid AC is number one OTC acid relief product with 24% share.

This article was originally published in The Tan Sheet

Executive Summary

J&J-MERCK PEPCID AC IS NUMBER ONE OTC ACID RELIEF PRODUCT with a market share of about 22% at the end of November, Merck Senior VP Judy Lewent told a meeting of securities analysts at the company's Whitehouse Station, N.J. headquarters Dec. 12. The OTC version of the H2 antagonist famotidine, launched in June, is "the number one product in the acid relief category, surpassing older antacid products and thus far successfully thwarting the challenge by [SmithKline Beecham's] Tagamet HB," Lewent declared.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts